683 Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

683 Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,000,000	Closed	-$1.59M	–	197
2018 Q4	$1.59M	Buy	+1,000,000	New	+$2.83M	0.1%	97
2017 Q3	–	Sell	-250,000	Closed	-$1.15M	–	131
2017 Q2	$1.15M	Buy	250,000 +50,000	+25%	+$201K	0.17%	76
2017 Q1	$842K	Buy	+200,000	New	+$830K	0.13%	80

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

683 Capital Management's ACHN Position: Q1 2019 in Review

683 Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2019, closing a stake of 1,000,000 shares — an estimated $1.59M sold.

683 Capital Management first reported a position in ACHN in Q1 2017 and held it in 3 quarters. The position peaked at $1.59M in Q4 2018. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

683 Capital Management reported no remaining Achillion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
683 Capital Management sold 1,000,000 Achillion Pharmaceuticals shares in Q1 2019, an estimated $1.59M.
683 Capital Management first reported a position in Achillion Pharmaceuticals in Q1 2017 and held it in 3 quarters.
683 Capital Management's Achillion Pharmaceuticals position peaked at $1.59M in Q4 2018.
110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on 683 Capital Management's 13F filing for Q1 2019, filed 15 May 2019.